Frankfurt - Delayed Quote ? EUR Hangzhou Tigermed Consulting Co., Ltd (5HZ1.F) Follow Compare 3.8800 -0.0800 (-2.02%) As of 9:15 AM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Tigermed Reports 2024 Interim Results Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its interim results for the first half of 2024, ended June 30, 2024 (the "Reporting Period"). PR Newswire ? 2 months ago HNGZY Veeva Systems' (VEEV) Vault EDC to Boost Tigermed's Workflow Veeva Systems' (VEEV) Vault EDC is likely to streamline key processes to accelerate study builds and make mid-study amendments with no downtime. Zacks ? 5 months ago VEEV BSX DVA Tigermed Reports Full Year 2023 Results Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2023 (the "Reporting Period"). PR Newswire ? 7 months ago HNGZY Performance Overview Trailing total returns as of 11/18/2024, which may include dividends or other distributions. Benchmark is SSE Composite Index Return 5HZ1.F SSE Composite Index YTD -9.53% +11.73% 1-Year -11.27% +8.82% 3-Year -66.12% -6.04%
